MYCN and neuroblastoma: In more details, Kocak-649 included 78 stage 4S NB patients, of which 17 were excluded for lack of information on patients’ survival, 4 for MYCN amplification, and 1 for missing data about MYCN status, thus leaving 56 patients (13 events) available for the analyses.